167992-81-6

Upstream product

• 67-56-1 methanol 
• 42760-52-1 4-Methyl-5-nitro-phthalic acid 
• 19438-61-0 4-methylphthalic anhydride 

Downstream Products

• 146271-57-0 dimethyl 4-fluoro-5-methylphthalate 
• 439126-19-9 dimethyl 4-amino-5-methylphthalate 
• 1026901-39-2 2,2-Dimethyl-propionic acid 5-{3-[(S)-2-({6-[(adamantan-1-ylmethyl)-carbamoyl]-1H-indole-5-carbonyl}-amino)-3-phenyl-propionylamino]-5-[1-(2,2-dimethyl-propionyloxymethyl)-1H-tetrazol-5-yl]-phenyl}-tetrazol-1-ylmethyl ester 
• 1026556-36-4 5-[(S)-2-({6-[(Adamantan-1-ylmethyl)-carbamoyl]-1H-indole-5-carbonyl}-amino)-3-(2-fluoro-phenyl)-propionylamino]-isophthalic acid dibenzyl ester 
• 1026346-99-5 5-((S)-2-{[6-(Cycloheptylmethyl-carbamoyl)-1H-indole-5-carbonyl]-amino}-3-phenyl-propionylamino)-isophthalic acid dibenzyl ester 
• 167992-88-3 5-[(S)-2-({6-[(Adamantan-1-ylmethyl)-carbamoyl]-1H-indole-5-carbonyl}-amino)-3-phenyl-propionylamino]-isophthalic acid dibenzyl ester 
• 338450-87-6 5-[(S)-2-({5-[(Adamantan-1-ylmethyl)-carbamoyl]-1H-indole-6-carbonyl}-amino)-3-phenyl-propionylamino]-isophthalic acid dibenzyl ester 
• 167992-95-2 5-(1S-(3,5-dibenzyloxycarbonylphenylaminocarbonyl)-2-phenylethylaminocarbonyl)-indole-6-carboxylic acid 
• 1026614-90-3 5-{(S)-2-[(5-Carboxy-1H-indole-6-carbonyl)-amino]-3-phenyl-propionylamino}-isophthalic acid dibenzyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10,Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Achieving Balanced Charge Transport and Favorable Blend Morphology in Non-Fullerene Solar Cells via Acceptor End Group Modification

Generally, the electron-withdrawing substitution on the end-capping group of the acceptor-donor-acceptor type small-molecule acceptor (SMA) narrows the optical bandgap, and the electron-donating group lifts the lowest unoccupied molecular orbital (LUMO) e

Polysubstituted benzocyclopentadione derivative-based A-D-A conjugated molecule and application thereof

The invention discloses a polysubstituted benzocyclopentadione derivative-based A-D-A conjugated molecule and application thereof. The application chemical structural general formula of the conjugatedmolecule is as shown in the specification. According to

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

Inhibitors of papilloma virus

A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DN

GASTIN AND CCK RECEPTOR LIGANDS

Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R 1 (m) represents up to 6 substituents, K represents--O--,--S--,--CH 2--,--N(R 2)--or--N(COR 2)--, in which R 2 is H or C 1 to C 3 alkyl, W is a carbonyl, sulfonyl or sulfinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description, and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors. STR1